비편평세포, 비소세포폐암 환자에서 erlotinib, gefitinib 및 pemetrexed의 효과
Clinical outcomes of erlotinib, gefitinib, or pemetrexed in patients with non-squamous, non-small-cell lung cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 본 연구는 비소세포폐암의 2차 이상의 항암 화학 요법에서 EGFR TKIs와 pemetrexed의 임상적인 특징에 따른 치료 성적을 비교함으로써 구제치료의 선택에 도움을 주고자 하였다방법: 2002년 2월부터 2009년 8월까지 부천 순천향대학교병원 혈액종양내과에서 비소세포폐암을 진단받은 환자들 중 편평상피암을 제외한 선암과 대세포암 환자들을 대상으로 하였으며 이들 중 gefitinib이나 erlotinib 및 pemetrexed로 치료받은 환자를 의무기록을 통해 후향적으로 조사하였다결과: 총 61명이 연구에 참여하였고 그 중 erlotinib군이 18명, gefitinib군은 18명, pemetrexed군은 25명이었으며 중앙관찰기간은 37개월(7-97개월)이었다. 세 군간에 반응율과 무진행 생존기간에는 의미있는 차이가 없었으며 EGFR TKIs 를 투여받은 환자들 중에서는 여성에서 보다 좋은 반응율은 보였고, erlotinib 을 투여받은 환자들 중 피부발진이 있었던 환자들과 Pemetrexed를 투여 받은 환자들 중 선암으로 진단된 경우 에서 무진행 생존기간이 의미있게 길었다. 결론: EGFR TKIs 와 Pemetrexed 는 모두 비편평세포암, 비소세포암 환자에서 2차 이상의 치료로 사용하였을 때 비교적 효과적이었으며 부작용도 적은 것으로 나타났다. 향후 EGKR TKIs 및 pemetrexed군 치료 효과 및 치료 효과에 영향을 미치는 다양한 임상적 예후인자에 대한 보다 많은 대규모 전향적 비교 연구가 필요할 것이다.
Abstract
Background/Aims: This study compared the clinical benefits of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) with pemetrexed to identify the clinical parameters that correlated with response. Methods: A retrospective chart review examined patients who were 1) treated with EGFR TKI or pemetrexed, 2) diagnosed with advanced non-squamous non-small-cell lung cancer, and 3) previously treated with platinum-based chemotherapy in Soonchunhyang Bucheon Hospital. Results: Sixty-one patients (18 erlotinib, 18 gefitinib, 25 pemetrexed) were investigated from February 2002 to August 2009. The median follow-up period was 37 months (7~97 months). Overall, their median age was 63 years, 41 patients were non-smokers, 57 patients had adenocarcinoma, and 55 patients were at stage IV. Twenty-one patients received the study drugs as second-line chemotherapy, and others as third-line or more. No significant differences in the overall response rate (erlotinib 33.3% vs. gefitinib 38.9% vs. pemetrexed 20.0%) and progression-free survival (erlotinib 1.9 months vs. gefitinib 3.0 months vs. pemetrexed 2.9 months) were found among the three groups. Female gender was related to a good response to EGFR TKIs (p=0.047). Skin rash in the erlotinib group (p=0.037) and adenocarcinoma in the pemetrexed group (p=0.02) were related to improved progression-free survival. Few side effects were reported. Conclusions: Both EGFR TKIs and pemetrexed therapy for non-squamous non-small-cell lung cancer were efficient and tolerable after the failure of first-line platinum-based chemotherapy. Further prospective studies are needed to validate the predictive role of the suggested clinical parameters in this study.
참고문헌 (18)
- Dempke WC, "Targeted therapies for non-small cell cancer", Lung Cancer, 67, pp.257~274 (2010)
- Goss GD, "Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 Study", J Clin Oncol, 28, pp.49~55 (2010)
- Pfister DG, "American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003", J Clin Oncol, 22, pp.330~353 (2004)
- Shepherd FA, "Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy", J Clin Oncol, 18, pp.2095~2103 (2000)
- Fossella FV, "Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: the TAX 320 Non-Small Cell Lung Cancer Study Group", J Clin Oncol, 18, pp.2354~2362 (2000)
- Kris MG, "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial", JAMA, 290, pp.2149~2158 (2003)
- Kim ES, "Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial", Lancet, 372, pp.1809~1818 (2008)
- Hanna N, "Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy", J Clin Oncol, 22, pp.1589~1597 (2004)
- Rudd RM, "Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non small cell lung cancer. a phase III randomized study of the London Cancer Group", J Clin Oncol, 23, pp.142~153 (2005)
- Martoni A, "Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer", Eur J Cancer, 41, pp.81~92 (2005)
- Pérez-Soler R, "Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer", J Clin Oncol, 22, pp.3238~3247 (2004)
- Han SW, "Predictive and prognostic impat of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib", J Clin Oncol, 23, pp.2493~2501 (2005)
- Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
- Paez JG, "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
- Pao W, "EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib", Proc Natl Acad Sci U S A, 101, pp.13306~13311 (2004)
- Park K, "A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer", Curr Med Res Opin, 22, pp.561~573 (2006)
- Mok TS, "Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- Mohamed MK, "Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer", Ann Oncol, 16, pp.780~785 (2005)